Omar Salamanca, MD, staff ophthalmologist, Orbis Flying Eye Hospital, discusses Orbis's tailored glaucoma training programs, which focus on hands-on surgical skills, early detection, telemedicine, and ...
FELIQS plans to conduct a Phase 1b/2 study of FLQ-101 (tROPhy-1 study) both in the US and Japan in the first quarter of 2025.
Formosa Pharmaceuticals has announced the completion and top-line results from CPN-303, a phase 3 clinical study of APP13007 ...
The Valeda Light Delivery System is for the treatment of patients with dry age-related macular degeneration (AMD).
The investigators conducted a randomized controlled trial of 60 patients who underwent monitored anesthesia care sedation for ...
Robert T. Chang, MD, from Stanford University discusses how large language models are transforming ophthalmology by enhancing ...
In an interview with David Hutton of Ophthalmology Times, Ash Abbey, MD, discusses the Phase 3 LUGANO trial for EYP-1901 in treating wet age-related macular degeneration. Abbey discusses the trial’s ...
Researchers receive $6.4 million grant from NEI to seek new treatment for blindness-causing diseases
Rensselaer researchers receive $6.4 million grant from NEI to seek new treatment for blindness-causing diseases.
Victoria Biousse, MD, from the Emory University in Atlanta, Georgia, shared insights on how ocular imaging in the emergency ...
Dropless cataract surgery eliminates postoperative eye drops, enhancing patient adherence and reducing complications like ...
A group of German researchers has discovered how tiny eye movements and the density of photoreceptors assist in visual acuity ...
Chronic therapy is essential for PCV patients, even after resolution of pigment epithelial detachment, to prevent recurrence.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback